Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia

Leukemia Research

Volumn 36, Issue 2, 2012, Pages 174-181

  Guillem, Vicent ^a   Amat, Paula ^a   Cervantes, Francisco ^b   Alvarez Larrán, Alberto ^c   Cervera, Jose ^c   Maffioli, Margherita ^b   Bellosillo, Beatriz ^d   Collado, María ^a   Marugán, Isabel ^a   Martínez Ruiz, Francisco ^e   Hernández Boluda, Juan Carlos ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Chronic myeloid leukemia; Genetic polymorphisms; Imatinib; Phosphatases; Suppressors of cytokine signaling

Indexed keywords

HYDROXYUREA; IMATINIB; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN TYROSINE KINASE INHIBITOR; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ADOLESCENT; ADULT; AGED; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FAILURE FREE SURVIVAL; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PTPN22 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SOCS1 GENE; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DNA; FEMALE; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; YOUNG ADULT;

EID: 84855202791     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.011     Document Type: Article

References (37)

1. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453.
2. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
3. Hernandez-Boluda J.C., Cervantes F. Prognostic factors in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:343-353.
4. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
5. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
6. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
7. Julien S.G., Dube N., Hardy S., Tremblay M.L. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 2011, 11:35-49.
8. Wormald S., Hilton D.J. Inhibitors of cytokine signal transduction. J Biol Chem 2004, 279:821-824.
9. Konig H., Holtz M., Modi H., Manley P., Holyoake T.L., Forman S.J., et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008, 22:748-755.
10. Chu S., Holtz M., Gupta M., Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004, 103:3167-3174.
11. Neviani P., Santhanam R., Oaks J.J., Eiring A.M., Notari M., Blaser B.W., et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007, 117:2408-2421.
12. Shimizu T., Miyakawa Y., Oda A., Kizaki M., Ikeda Y. STI571-resistant KT-1 cells are sensitive to interferon-alpha accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1. Exp Hematol 2003, 31:601-608.
13. Koyama N., Koschmieder S., Tyagi S., Portero-Robles I., Chromic J., Myloch S., et al. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571. Clin Cancer Res 2006, 12:2025-2031.
14. Dong L.M., Potter J.D., White E., Ulrich C.M., Cardon L.R., Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 2008, 299:2423-2436.
15. McLeod H.L., Evans W.E., Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001, 41:101-121.
16. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
17. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99:3472-3475.
18. Yuan H.Y., Chiou J.J., Tseng W.H., Liu C.H., Liu C.K., Lin Y.J., et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006, 34:W635-W641.
19. Sole X., Guino E., Valls J., Iniesta R., Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006, 22:1928-1929.
20. Hernandez-Boluda J.C., Collado M., Roda D., Amat P., Tormo M., Marugan I. Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia. Leuk Res 2009, 33:589-592.
21. Cortes J.E., Talpaz M., Giles F., O'Brien S., Rios M.B., Shan J., et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003, 101:3794-3800.
22. Marin D., Milojkovic D., Olavarria E., Khorashad J.S., de Lavallade H., Reid A.G., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
23. White D.L., Saunders V.A., Dang P., Engler J., Venables A., Zrim S., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110:4064-4072.
24. Bazeos A., Marin D., Reid A.G., Gerrard G., Milojkovic D., May P.C., et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 2010, 24:1243-1245.
25. White D.L., Saunders V.A., Dang P., Engler J., Hughes T.P. OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia 2010, 24:1962-1965.
26. Dulucq S., Bouchet S., Turcq B., Lippert E., Etienne G., Reiffers J., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112:2024-2027.
27. Maffioli M., Camos M., Gaya A., Hernandez-Boluda J.C., Alvarez-Larran A., Domingo A., et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res 2011, 10.1016/j.leukres.2010.12.004.
28. Kim D.H., Kong J.H., Byeun J.Y., Jung C.W., Xu W., Liu X., et al. The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2010, 16:5339-5350.
29. Liu T.C., Lin S.F., Chang J.G., Yang M.Y., Hung S.Y., Chang C.S. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 2003, 123:654-661.
30. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Cervantes F., Barrios M., Colomer D., et al. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica 2004, 89:42-48.
31. Saudemont A., Hamrouni A., Marchetti P., Liu J., Jouy N., Hetuin D., et al. Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res 2007, 67:4491-4498.
32. Chien W., Tidow N., Williamson E.A., Shih L.Y., Krug U., Kettenbach A., et al. Characterization of a myeloid tyrosine phosphatase Lyp, and its role in the Bcr-Abl signal transduction pathway. J Biol Chem 2003, 278:27413-27420.
33. Zhang W.W., Cortes J.E., Yao H., Zhang L., Reddy N.G., Jabbour E., et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009, 27:3642-3649.
34. Villuendas R., Steegmann J.L., Pollan M., Tracey L., Granda A., Fernandez-Ruiz E., et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006, 20:1047-1054.
35. Harada M., Nakashima K., Hirota T., Shimizu M., Doi S., Fujita K., et al. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am J Respir Cell Mol Biol 2007, 36:491-496.
36. Steck A.K., Baschal E.E., Jasinski J.M., Boehm B.O., Bottini N., Concannon P., et al. rs2476601T allele (R620W) defines high-risk PTPN22 type I diabetes-associated haplotypes with preliminary evidence for an additional protective haplotype. Genes Immun 2009, 10(Suppl. 1):S21-S26.
37. Kyogoku C., Langefeld C.D., Ortmann W.A., Lee A., Selby S., Carlton V.E., et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004, 75:504-507.